Trials that use: Odds ratio
New to this method? Read the tutorial →
5,976 results
- OSU Plate Waste Study: Complete Statistical AnalysisIndependent statistical analysis of OSU Plate Waste Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02790502).
- OTBB2Independent statistical analysis of Evaluation of Tolerance, Suckling and Food Intake After Repeated Nasals Administrations of Oxytocin in PWS Infants: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- OTT15-04Independent statistical analysis of Multicentre Study to Determine the Feasibility of Using an Integrated Consent Model to Compare Three Standard of Care Regimens for The Treatment of Triple-Negative Breast Cancer in the…
- Otteroo Case Series: Complete Statistical AnalysisIndependent statistical analysis of Otteroo Case Series: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03502265).
- OTX-14-003: A Phase 3 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Ocular Inflammation and Pain After Cataract Surgery: Complete Statistical AnalysisIndependent statistical analysis of OTX-14-003: A Phase 3 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Ocular Inflammation and Pain After Cataract Surgery: primary endpoint results, effect estimate…
- OU-SCC-PI-4GIndependent statistical analysis of PARP Inhibition for Gliomas (PI-4G or π4g): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05297864).
- Outcomes of Anterior Colporrhaphy Versus Graft Reinforced Anterior Prolapse Repair: Complete Statistical AnalysisIndependent statistical analysis of Outcomes of Anterior Colporrhaphy Versus Graft Reinforced Anterior Prolapse Repair: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00535301).
- Outpatient Antibiotics Following Previable Rupture of Membranes (pPPROM) Between 18 0/7 and 22 6/7 Weeks Gestational Age: Complete Statistical AnalysisIndependent statistical analysis of Outpatient Antibiotics Following Previable Rupture of Membranes (pPPROM) Between 18 0/7 and 22 6/7 Weeks Gestational Age: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Over Active Bladder Patients Having Sling Surgery: Complete Statistical AnalysisIndependent statistical analysis of Over Active Bladder Patients Having Sling Surgery: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00852696).
- Overnight Pant Study for Children With Nocturnal Enuresis: Complete Statistical AnalysisIndependent statistical analysis of Overnight Pant Study for Children With Nocturnal Enuresis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05178641).
- Ovulation Induction in Women With Clomiphene Citrate Resistant PCOS: Complete Statistical AnalysisIndependent statistical analysis of Ovulation Induction in Women With Clomiphene Citrate Resistant PCOS: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01909141).
- Oxaliplatin and Docetaxel as First-line Therapy for Advanced Non-small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Oxaliplatin and Docetaxel as First-line Therapy for Advanced Non-small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Oxaliplatin Microdosing Assay in Predicting Exposure and Sensitivity to Oxaliplatin-Based Chemotherapy: Complete Statistical AnalysisIndependent statistical analysis of Oxaliplatin Microdosing Assay in Predicting Exposure and Sensitivity to Oxaliplatin-Based Chemotherapy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Oxaliplatin, Fludarabine, Cytarabine and Rituximab in Richter’s Syndrome, Refractory CLL and PLL: Complete Statistical AnalysisIndependent statistical analysis of Oxaliplatin, Fludarabine, Cytarabine and Rituximab in Richter's Syndrome, Refractory CLL and PLL: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Oxaliplatin, Gemcitabine and Bevacizumab in Women With Recurrent Mullerian Carcinoma: Complete Statistical AnalysisIndependent statistical analysis of Oxaliplatin, Gemcitabine and Bevacizumab in Women With Recurrent Mullerian Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00418093).
- Oxidative Phosphorylation Inhibitor IACS-010759 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Oxidative Phosphorylation Inhibitor IACS-010759 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Oxygen Monitoring of Patients After Surgery on the Hospital General Care Floor: Complete Statistical AnalysisIndependent statistical analysis of Oxygen Monitoring of Patients After Surgery on the Hospital General Care Floor: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Oxygen Reserve Index: Utility as Early Warning for Desaturation in Morbidly Obese Patients: Complete Statistical AnalysisIndependent statistical analysis of Oxygen Reserve Index: Utility as Early Warning for Desaturation in Morbidly Obese Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- OZGAMIndependent statistical analysis of Effectiveness of OZ439 as a Gametocytocidal and Transmission Blocking Agent: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02431650).
- P2Independent statistical analysis of PROSPECT II & PROSPECT ABSORB - an Integrated Natural History Study and Randomized Trial.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- P3: Pacemaker Patient Profiling Study: Complete Statistical AnalysisIndependent statistical analysis of P3: Pacemaker Patient Profiling Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00294060).
- PACE-RBBBIndependent statistical analysis of Pacing Affects Cardiovascular Endpoints in Patients With Right Bundle-Branch Block (The PACE-RBBB Trial): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- PACERIndependent statistical analysis of Providing Adolescent Contraception in the Emergency Room: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02475980).
- PACIFIC-AMIIndependent statistical analysis of Study to Gather Information About the Proper Dosing and Safety of the Oral FXIa Inhibitor BAY 2433334 in Patients Following an Acute Heart Attack: primary endpoint results, effect…
- Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa: Complete Statistical AnalysisIndependent statistical analysis of Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01796197).
- Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: Complete Statistical AnalysisIndependent statistical analysis of Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size…
- Paclitaxel and Carboplatin in Treating Patients With Persistent or Recurrent Stage III or Stage IV Uterine Cancer: Complete Statistical AnalysisIndependent statistical analysis of Paclitaxel and Carboplatin in Treating Patients With Persistent or Recurrent Stage III or Stage IV Uterine Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Paclitaxel and Carboplatin or Temozolomide in Treating Patients With Stage IV Melanoma: Complete Statistical AnalysisIndependent statistical analysis of Paclitaxel and Carboplatin or Temozolomide in Treating Patients With Stage IV Melanoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Paclitaxel in Treating Patients With Ovarian Stromal Cancer: Complete Statistical AnalysisIndependent statistical analysis of Paclitaxel in Treating Patients With Ovarian Stromal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00006227).
- Paclitaxel, Bevacizumab and Pemetrexed in Patients With Untreated, Advanced Non-Small Cell Lung Cancer Using Web-Based Data Collection, Patient Self-Reporting of Adverse Effects and Automated Response Assessment: Complete Statistical AnalysisIndependent statistical analysis of Paclitaxel, Bevacizumab and Pemetrexed in Patients With Untreated, Advanced Non-Small Cell Lung Cancer Using Web-Based Data Collection, Patient Self-Reporting of Adverse Effects and Automated Response Assessment: primary endpoint…
- Paclitaxel, Carboplatin, and Panitumumab in Treating Patients With Metastatic Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Paclitaxel, Carboplatin, and Panitumumab in Treating Patients With Metastatic Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS): Complete Statistical AnalysisIndependent statistical analysis of Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02469415).
- PACSIndependent statistical analysis of Cranberry for UTI Prevention in Residents of Long Term Care Facilities: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- PACTIndependent statistical analysis of Parent Acceptance and Commitment Therapy (PACT) for Parents of Children With Pediatric Feeding Disorder: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- PADD-ONIndependent statistical analysis of Peg-interferon ADDed to an Ongoing Nucleos(t)Ide Based Treatment in Patients With Chronic Hepatitis B to Induce Decrease of HBs-Antigen: primary endpoint results, effect estimate with confidence interval, sample-size…
- PAI vs FNBIndependent statistical analysis of Analgesia After Total Knee Arthroplasty: Peri-Articular Injection Versus Epidural + Femoral Nerve Blockade: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Palatability and Tolerability of Deferasirox Taken With Meals, With Different Liquids or Crushed and Added to Food: Complete Statistical AnalysisIndependent statistical analysis of Palatability and Tolerability of Deferasirox Taken With Meals, With Different Liquids or Crushed and Added to Food: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3): Complete Statistical AnalysisIndependent statistical analysis of Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Palivizumab for Prevention of Severe Respiratory Syncytial Virus Infection in Russian Children: Complete Statistical AnalysisIndependent statistical analysis of Palivizumab for Prevention of Severe Respiratory Syncytial Virus Infection in Russian Children: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- PALOMA-2Independent statistical analysis of PALOMA-2 (NCT01740427), a randomized phase 3 trial of palbociclib plus letrozole versus placebo plus letrozole in postmenopausal women with ER+/HER2- advanced breast cancer.
- PALOMA-4Independent statistical analysis of PALOMA-4, a randomized phase 3 trial comparing palbociclib plus letrozole with placebo plus letrozole in Asian postmenopausal women with ER+/HER2- advanced breast cancer.
- Palonosetron, Ondansetron, and Dexamethasone for Delayed Nausea and Vomiting in Autologous Transplant Patients: Complete Statistical AnalysisIndependent statistical analysis of Palonosetron, Ondansetron, and Dexamethasone for Delayed Nausea and Vomiting in Autologous Transplant Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Palu-COVIDIndependent statistical analysis of Malaria as a Protection Factor Against Severe COVID-19 (Known as SARS-COV-2) in the Democratic Republic of Congo (Palu-COVID): primary endpoint results, effect estimate with confidence interval, sample-size planning…
- PANCAX-3Independent statistical analysis of Pancreaze (Pancrelipase) for Patients With Pancreatic Adenocarcinoma With Cachexia and Exocrine Pancreatic Insufficiency: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Panobinostat (LBH589): Acute Graft Versus Host Disease (aGVHD) Prevention: Complete Statistical AnalysisIndependent statistical analysis of Panobinostat (LBH589): Acute Graft Versus Host Disease (aGVHD) Prevention: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02588339).
- Panobinostat, Carfilzomib, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Panobinostat, Carfilzomib, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size…